Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
সব দামের পরিবর্তন →Save on this medicine
Same active ingredient — pay up to 57% less
These brands contain the same active ingredient (Capecitabine). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
ইঙ্গিত ও ব্যবহার
Syntabine এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
Adults:
Monotherapy: 1250 mg/m2 taken by mouth twice daily for 2 weeks, followed by a one-week rest period, in 3-week cycles. Adjuvant treatment: Recommended for a total of 6 months (8 cycles). In combination with docetaxel: The recommended dose of Capecitabine is 1250 mg/m2 twice daily for 2 weeks, followed by a 7-day rest period, combined with docetaxel at 75 mg/m2 given as a 1-hour IV infusion every 3 weeks. The Capecitabine dose may need to be individualised to optimise patient management. In patients with moderate renal impairment, the Capecitabine dose must be reduced by 25%. Example: A person weighing 64 kg with a height of 1.64 m has a body surface area of 1.7 m2 and should take 4 tablets of 500 mg and 1 tablet of 150 mg two times daily. The tablets should be taken in the morning and evening as prescribed by the doctor. They should be taken within 30 minutes after the end of a meal (breakfast and dinner) and swallowed whole with water. The tablets should not be cut or crushed. Capecitabine should only be prescribed by a doctor experienced in the use of anticancer medicines.
পার্শ্বপ্রতিক্রিয়া
Abdominal pain, rash, dry or itchy skin, tiredness, loss of appetite (anorexia), diarrhea, vomiting, nausea, stomatitis, hand-and-foot skin reaction, fever, infection, chest pain, and Stevens-Johnson syndrome.
সতর্কতা ও নিষেধাজ্ঞা
Warnings & Precautions
Coagulopathy: Anticoagulant response should be monitored (e.g. INR) and the anticoagulant dose adjusted accordingly. Otherwise, bleeding or death may result. Diarrhea: Caparen treatment should be stopped immediately until diarrhea resolves or decreases to grade 1. Standard antidiarrheal treatments are recommended. Otherwise, it may become severe. Cardiotoxicity: Common in patients with a prior history of coronary artery disease. Increased risk of severe or fatal adverse reactions in patients with low or absent dihydropyrimidine dehydrogenase (DPD) activity: Caparen should be withheld or permanently discontinued in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of DPD activity. Dehydration and renal failure: Caparen treatment should be stopped until dehydration is corrected. There is a potential risk of acute renal failure secondary to dehydration. Mucocutaneous and dermatologic toxicity: Severe mucocutaneous reactions, Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported. Caparen should be permanently discontinued in patients who experience a severe mucocutaneous reaction during treatment. Caparen may induce hand-and-foot syndrome. Caparen treatment should be interrupted until the hand-and-foot syndrome event resolves or decreases in intensity. Hyperbilirubinemia: Caparen treatment should be interrupted immediately until the hyperbilirubinemia resolves or decreases in intensity. Hematologic: Patients should not be treated with neutrophil counts <1.5x109/L or thrombocyte counts <100x109/L.
নিষেধাজ্ঞা
Severe renal impairment; hypersensitivity; leucopenia, neutropenia or thrombocytopenia; severe reactions to fluoropyrimidine therapy; complete DPD deficiency; pregnant or breast-feeding.